What's Happening?
Immunome, Inc. has presented preclinical data demonstrating that its proprietary antibody-drug conjugate (ADC) payload, HC74, can overcome multiple mechanisms of ADC resistance. HC74, a novel topoisomerase I inhibitor, is used in the ROR1-targeted ADC IM-1021,
currently in Phase 1 trials. The data, presented at an international cancer therapeutics conference, showed that HC74 effectively bypasses resistance mechanisms such as drug efflux and target heterogeneity, exhibiting high membrane permeability and robust cytotoxicity in preclinical models.
Why It's Important?
The ability of HC74 to overcome common resistance mechanisms in ADC therapies represents a significant advancement in cancer treatment. ADCs are a promising class of cancer therapeutics, but resistance has limited their effectiveness. By addressing these challenges, HC74 could enhance the efficacy of ADCs, offering new hope for patients with resistant cancers. This development positions Immunome as a leader in the field, potentially transforming the landscape of targeted cancer therapies.
What's Next?
Immunome plans to advance HC74 through further clinical trials, aiming to validate its efficacy and safety in human patients. The company is also exploring the potential of HC74 in combination with other therapies, which could lead to more comprehensive treatment strategies. As research progresses, HC74 could become a cornerstone in the development of next-generation ADCs, improving outcomes for cancer patients worldwide.
